{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:37:32Z","timestamp":1764175052290,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["71573239"],"award-info":[{"award-number":["71573239"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiretroviral treatment (ART) and pre-exposure prophylaxis (PrEP) for HIV-serodiscordant couples, effectively reduce mortality, transmission events and influence quality of life at the expense of increased costs. We aimed to evaluate health economics of antiretroviral-based strategies for HIV-serodiscordant couples in the China context. A deterministic model of HIV evolution and transmission within a cohort of serodiscordant couples was parameterized using the real-world database of Zhoukou city and published literature. We evaluated the mid-ART (a historical strategy, initiating ART with CD4\u2009&lt;\u2009500\u00a0cells\/mm<jats:sup>3<\/jats:sup>), early-ART (the current strategy, offering ART regardless of CD4 cell counts) and a hypothetical strategy (early-ART combined short-term daily PrEP) versus the late-ART (the baseline strategy, initiating ART with CD4\u2009&lt;\u2009350\u00a0cells\/mm<jats:sup>3<\/jats:sup>) offered by 2008 national guidelines. We estimated the incremental cost-effectiveness ratios (ICER) and incremental cost-utility ratios (ICUR) from a societal perspective, derived by clinical benefits and HIV-caused life quality respectively, and portrayed their changes over a 0\u201330 year\u2019s timeframe. The model projections indicated that the antiretroviral-based interventions were more likely to obtain clinical benefits but difficult to improve quality of life, and cumulative ICER and ICUR were generally decreasing without achieving cost-saving. Scale-up access to ART for the HIV-positive among serodiscordant couples was easily fallen within the range of paying for incremental life-years and quality adjusted life years by the societal willingness. The hypothetical strategy had the potential to prevent most seroconversion events within marriages but required enormous upfront costs, thus it took a long time to reach established thresholds. The current strategy of early-ART is the most cost-effective. Clarifying the obstacles of high cost of PrEP and improving life quality for HIV-serodiscordant couples have emerged as an urgent requisition.<\/jats:p>","DOI":"10.1038\/s41598-021-93443-x","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T10:04:51Z","timestamp":1625652291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health economics modeling of antiretroviral interventions amongst HIV serodiscordant couples"],"prefix":"10.1038","volume":"11","author":[{"given":"Haisheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"93443_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30482-6","author":"N Ford","year":"2017","unstructured":"Ford, N. et al. The WHO public health approach to HIV treatment and care: Looking back and looking ahead. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(17)30482-6 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"93443_CR2","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/QAI.0000000000001210","volume":"74","author":"JF Morton","year":"2017","unstructured":"Morton, J. F. et al. Counseling framework for HIV-serodiscordant couples on the integrated use of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention. JAIDS J. Acquir. Immune Defic. Syndr. 74, S15\u2013S22. https:\/\/doi.org\/10.1097\/QAI.0000000000001210 (2017).","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"93443_CR3","unstructured":"WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva (2015)."},{"key":"93443_CR4","unstructured":"National Health Commission of P.R. China. Notice on adjusting the standards of free antiretroviral therapy for HIV positive patients. http:\/\/www.nhc.gov.cn\/yzygj\/s3593\/201606\/0b0fa78e10dc41328e842b1bf9cd433e.shtml. Accessed 18 Dec 2018 (2016)."},{"key":"93443_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4275-x","author":"QH Hu","year":"2019","unstructured":"Hu, Q. H. et al. Efficacy and cost-effectiveness of early antiretroviral therapy and partners\u2019 pre-exposure prophylaxis among men who have sex with men in Shenyang, China: A prospective cohort and costing study. BMC Infect. Dis. https:\/\/doi.org\/10.1186\/s12879-019-4275-x (2019).","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"93443_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10461-018-2205-3","volume":"23","author":"Z Lei","year":"2019","unstructured":"Lei, Z. et al. Modelling the epidemiological impact and cost-effectiveness of PrEP for HIV transmission in MSM in China. AIDS Behav. 23(2), 523\u2013533. https:\/\/doi.org\/10.1007\/s10461-018-2205-3 (2019).","journal-title":"AIDS Behav."},{"issue":"2","key":"93443_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.2016.5148","volume":"316","author":"AJ Rodger","year":"2016","unstructured":"Rodger, A. J. et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive part. JAMA 316(2), 171\u2013181. https:\/\/doi.org\/10.1001\/jama.2016.5148 (2016).","journal-title":"JAMA"},{"issue":"5","key":"93443_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/cid\/cix878","volume":"66","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China: A nationwide, retrospective cohort study. Clin. Infect. Dis. 66(5), 727\u2013734. https:\/\/doi.org\/10.1093\/cid\/cix878 (2018).","journal-title":"Clin. Infect. Dis."},{"issue":"9899","key":"93443_CR9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(12)61898-4","volume":"382","author":"Z Jia","year":"2013","unstructured":"Jia, Z. et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003\u201311): A national observational cohort study. Lancet 382(9899), 1195\u20131203. https:\/\/doi.org\/10.1016\/S0140-6736(12)61898-4 (2013).","journal-title":"Lancet"},{"key":"93443_CR10","unstructured":"The Joint United Nations Programme on HIV and AIDS. 2015 China AIDS response progress report. http:\/\/www.unaids.org\/sites\/default\/files\/ country\/documents\/CHN_narrative_report_2015.pdf. Accessed 18 Dec 2018 (2015)."},{"issue":"1","key":"93443_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cid\/civ200","volume":"61","author":"MK Smith","year":"2015","unstructured":"Smith, M. K. et al. Treatment to prevent HIV transmission in serodiscordant couples in Henan, China. Clin. Infect. Dis. 61(1), 111. https:\/\/doi.org\/10.1093\/cid\/civ200 (2015).","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"93443_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002099","volume":"13","author":"JM Baeten","year":"2016","unstructured":"Baeten, J. M. et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: A prospective implementation study in Kenya and Uganda. PLoS Med. 13(8), e1002099. https:\/\/doi.org\/10.1371\/journal.pmed.1002099 (2016).","journal-title":"PLoS Med."},{"issue":"3","key":"93443_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1814556","volume":"381","author":"RJ Hayes","year":"2019","unstructured":"Hayes, R. J. et al. Effect of universal testing and treatment on HIV incidence-HPTN 071 (PopART). N. Engl. J. Med. 381(3), 207\u2013218. https:\/\/doi.org\/10.1056\/NEJMoa1814556 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"93443_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001123","volume":"8","author":"TB Hallett","year":"2011","unstructured":"Hallett, T. B. et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: A modelling study. PLoS Med. 8(11), e1001123. https:\/\/doi.org\/10.1371\/journal.pmed.1001123 (2011).","journal-title":"PLoS Med."},{"issue":"8","key":"93443_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1136\/sextrans-2012-050891","volume":"89","author":"S Verguet","year":"2013","unstructured":"Verguet, S., Stalcup, M. & Walsh, J. A. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?. Sex. Transm. Infect. 89(8), 628\u2013634. https:\/\/doi.org\/10.1136\/sextrans-2012-050891 (2013).","journal-title":"Sex. Transm. Infect."},{"issue":"12","key":"93443_CR16","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1473-3099(16)30311-5","volume":"16","author":"BE Nichols","year":"2016","unstructured":"Nichols, B. E. et al. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: A mathematical modelling study. Lancet Infect. Dis. 16(12), 1423\u20131429. https:\/\/doi.org\/10.1016\/S1473-3099(16)30311-5 (2016).","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"93443_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5582\/ddt.2019.01028","volume":"13","author":"Q Tang","year":"2019","unstructured":"Tang, Q. & Lu, H. Immediate antiviral therapy for HIV-infected persons faces with various obstacles. Drug Discov. Ther. 13(3), 172\u2013174. https:\/\/doi.org\/10.5582\/ddt.2019.01028 (2019).","journal-title":"Drug Discov. Ther."},{"key":"93443_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30230-9","author":"A Pandey","year":"2019","unstructured":"Pandey, A. & Galvani, A. P. The global burden of HIV and prospects for control. Lancet HIV https:\/\/doi.org\/10.1016\/S2352-3018(19)30230-9 (2019).","journal-title":"Lancet HIV"},{"key":"93443_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30334-0","author":"KS Harmon","year":"2019","unstructured":"Harmon, K. S. et al. Reorienting health systems to care for people with HIV beyond viral suppression. Lancet HIV https:\/\/doi.org\/10.1016\/S2352-3018(19)30334-0 (2019).","journal-title":"Lancet HIV"},{"issue":"10","key":"93443_CR20","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/cid\/cis225","volume":"54","author":"RP Walensky","year":"2012","unstructured":"Walensky, R. P. et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin. Infect. Dis. 54(10), 1504\u20131513. https:\/\/doi.org\/10.1093\/cid\/cis225 (2012).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"93443_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/QAD.0b013e32835ca2dd","volume":"27","author":"I Cremin","year":"2013","unstructured":"Cremin, I. et al. The new role of antiretrovirals in combination HIV prevention: A mathematical modelling analysis. AIDS 27(3), 447\u2013458. https:\/\/doi.org\/10.1097\/QAD.0b013e32835ca2dd (2013).","journal-title":"AIDS"},{"issue":"15","key":"93443_CR22","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/QAD.0000000000000798","volume":"29","author":"KM Mitchell","year":"2015","unstructured":"Mitchell, K. M. et al. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. AIDS 29(15), 2035\u20132044. https:\/\/doi.org\/10.1097\/QAD.0000000000000798 (2015).","journal-title":"AIDS"},{"issue":"4 Suppl 3","key":"93443_CR23","doi-asserted-by":"publisher","first-page":"20013","DOI":"10.7448\/IAS.18.4.20013","volume":"18","author":"Y Roger","year":"2015","unstructured":"Roger, Y. et al. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. J. Int. AIDS Soc. 18(4 Suppl 3), 20013. https:\/\/doi.org\/10.7448\/IAS.18.4.20013 (2015).","journal-title":"J. Int. AIDS Soc."},{"key":"93443_CR24","unstructured":"World Health Organization. Guidance on Couples HIV Testing and Counselling including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples Recommendations for a public health approach (2010)."},{"key":"93443_CR25","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1186\/s12879-018-3551-5","volume":"18","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Changing epidemiological patterns of HIV and AIDS in China in the post-SARS era identified by the nationwide surveillance system. BMC Infect. Dis. 18, 700. https:\/\/doi.org\/10.1186\/s12879-018-3551-5 (2018).","journal-title":"BMC Infect. Dis."},{"key":"93443_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2012.661837","author":"L Wang","year":"2012","unstructured":"Wang, L. et al. HIV seroconversion and prevalence rates in heterosexual discordant couples in China: A systematic review and meta-analysis. AIDS Care https:\/\/doi.org\/10.1080\/09540121.2012.661837 (2012).","journal-title":"AIDS Care"},{"issue":"6","key":"93443_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021839","volume":"6","author":"D Shan","year":"2011","unstructured":"Shan, D. et al. Quality of life and related factors among HIV-positive spouses from serodiscordant couples under antiretroviral therapy in Henan Province, China. PLoS\u00a0One 6(6), e21839. https:\/\/doi.org\/10.1371\/journal.pone.0021839 (2011).","journal-title":"PLoS\u00a0One"},{"issue":"8","key":"93443_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135705","volume":"10","author":"M Liping","year":"2015","unstructured":"Liping, M., Peng, X., Haijiang, L., Lahong, J. & Fan, L. Quality of life of people living with HIV\/AIDS: A cross-sectional study in Zhejiang Province, China. PLoS\u00a0One 10(8), e0135705. https:\/\/doi.org\/10.1371\/journal.pone.0135705 (2015).","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"93443_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s12879-019-3976-5","volume":"19","author":"X Wang","year":"2019","unstructured":"Wang, X., Guo, G., Zheng, J. & Lu, L. Cost-effectiveness of option B+ in prevention of mother-to-child transmission of HIV in Yunnan Province, China. BMC Infect. Dis. 19(1), 517. https:\/\/doi.org\/10.1186\/s12879-019-3976-5 (2019).","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"93443_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11904-016-0303-2","volume":"13","author":"MM Jacobsen","year":"2016","unstructured":"Jacobsen, M. M. & Walensky, R. P. Modeling and cost-effectiveness in HIV prevention. Curr HIV\/AIDS Rep. 13(1), 64\u201375. https:\/\/doi.org\/10.1007\/s11904-016-0303-2 (2016).","journal-title":"Curr HIV\/AIDS Rep."},{"key":"93443_CR31","unstructured":"World Health Organization. Cost effectiveness and strategic planning (whochoice) policy brief. Geneva: World Health Organization. http:\/\/www.who.int\/choice\/cost-effectiveness\/generalized\/en\/. Accessed 18 Dec 2019 (2018)."},{"key":"93443_CR32","unstructured":"National Bureau of Statistics of China. http:\/\/www.stats.gov.cn."},{"issue":"18","key":"93443_CR33","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJMsa1214720","volume":"369","author":"RP Walensky","year":"2013","unstructured":"Walensky, R. P. et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N. Engl. J. Med. 369(18), 1715\u20131725. https:\/\/doi.org\/10.1056\/NEJMsa1214720 (2013).","journal-title":"N. Engl. J. Med."},{"key":"93443_CR34","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost Effectiveness in Health and Medicine","author":"MR Gold","year":"1996","unstructured":"Gold, M. R., Siegel, J., Russell, L. & Weinstein, M. Cost Effectiveness in Health and Medicine (Oxford University Press, 1996)."},{"issue":"5","key":"93443_CR35","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/QAI.0b013e3182976891","volume":"63","author":"B Nosyk","year":"2013","unstructured":"Nosyk, B. et al. HIV-1 disease progression during highly active antiretroviral therapy: An application using population-level data in British Columbia: 1996\u20132011. J. Acquir. Immune Defic. Syndr. 63(5), 653. https:\/\/doi.org\/10.1097\/QAI.0b013e3182976891 (2013).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"93443_CR36","first-page":"54","volume":"24","author":"GY Ma","year":"2013","unstructured":"Ma, G. Y., Chen, H. Y. & Chen, J. Cohort study on the transmission of human immunodeficiency virus between spouses. J. Public Health Prev. Med. 24, 54\u201356 (2013).","journal-title":"J. Public Health Prev. Med."},{"key":"93443_CR37","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(00)04331-2","volume":"357","author":"RH Gray","year":"2001","unstructured":"Gray, R. H. et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357, 1149\u20131153 (2001).","journal-title":"Lancet"},{"issue":"12","key":"93443_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.7326\/0003-4819-153-12-201012210-00004","volume":"153","author":"EF Long","year":"2010","unstructured":"Long, E. F., Brandeau, M. L. & Owens, D. K. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann. Intern. Med. 153(12), 778\u2013789. https:\/\/doi.org\/10.7326\/0003-4819-153-12-201012210-00004 (2010).","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"93443_CR39","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/S2352-3018(15)00127-7","volume":"2","author":"B Nosyk","year":"2015","unstructured":"Nosyk, B. et al. Modelling the cost-effectiveness of population-level HAART expansion in British Columbia. Lancet HIV 2(9), e393-400. https:\/\/doi.org\/10.1016\/S2352-3018(15)00127-7 (2015).","journal-title":"Lancet HIV"},{"issue":"10","key":"93443_CR40","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/S2352-3018(17)30123-6","volume":"4","author":"RF Baggaley","year":"2017","unstructured":"Baggaley, R. F. et al. Cost-effectiveness of screening for HIV in primary care: A health economics modelling analysis. Lancet HIV 4(10), e465\u2013e474. https:\/\/doi.org\/10.1016\/S2352-3018(17)30123-6 (2017).","journal-title":"Lancet HIV"},{"issue":"9","key":"93443_CR41","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/S2352-3018(15)00127-7","volume":"2","author":"B Nosyk","year":"2015","unstructured":"Nosyk, B., Min, J. E., Lima, V. D., Hogg, R. S. & Montaner, J. S. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: A modelling study. Lancet HIV 2(9), e393\u2013e400. https:\/\/doi.org\/10.1016\/S2352-3018(15)00127-7 (2015).","journal-title":"Lancet HIV"},{"key":"93443_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30293-0","author":"J Xu","year":"2019","unstructured":"Xu, J., Tang, W., Zhang, F. & Shang, H. PrEP in China: Choices are ahead. Lancet HIV. https:\/\/doi.org\/10.1016\/S2352-3018(19)30293-0 (2019).","journal-title":"Lancet HIV."},{"key":"93443_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001692","author":"S Lodi","year":"2017","unstructured":"Lodi, S. et al. Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. AIDS https:\/\/doi.org\/10.1097\/QAD.0000000000001692 (2017).","journal-title":"AIDS"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93443-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93443-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93443-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T19:26:24Z","timestamp":1699212384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93443-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93443"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93443-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13967"}}